Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc. has showcased promising advancements in its portfolio, particularly with the introduction of KRRO-121, a subcutaneous RNA editing drug aimed at stabilizing glutamine synthetase and enhancing ammonia clearance in disease conditions. The drug has demonstrated robust liver uptake and improved safety profiles in non-human primates, indicating its potential to address significant unmet medical needs in conditions that could exceed a market potential of $3.5 billion. With an impending IND filing projected for the second half of 2026, coupled with demonstration of up to 40% editing efficacy, Korro Bio is well-positioned to capitalize on its innovative platform for RNA editing, bolstering optimism surrounding its financial prospects.

Bears say

Korro Bio faces significant challenges that contribute to a negative outlook on its stock, primarily due to recent disappointing results from its KRRO-110 AATD program and the introduction of KRRO-121 amid ongoing development risks. Key concerns include potential delays in clinical trials, the failure to produce favorable clinical data from its pipeline candidates, and the possibility of long-term dilution impacting shareholder value. Additionally, the risk of regulatory disagreements over data interpretations and competitive advancements in treatment methods further undermine the company's market positioning and financial stability.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.